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Skin immune deposits at the basement membrane zone 
have been demonstrated by functional assays to activate 
complement. This important biologic function has not 
yet been explored for immune deposits present in other 
locations mainly because many cytoplasmic structures 
in the skin have the capacity to activate the complement 
cascade by the classical pathway. 
In this study the capacity of immune deposits to acti -
vate directly the alternative pathway was examined 
using a functional guinea pig C3 binding test. This test 
was devised so as to avoid complement activation by 
normal cutaneous structures, thus it did not examine the 
capacity of immune reactants to activate the classical 
pathway. The main findings were that (1) alternative 
pathway activation could be demonstrated only when 
human C3 deposits were seen by direct immunofluores-
cence, but not all C3 deposits were found to activate the 
alternative pathway; (2) such activation was restricted 
to vascular deposits; (3) the phlogistic potential of the 
immune deposits correlated with serologic evidence of 
ongoing immune reactions, i.e. , hypocomplementemia 
and circulating immune complexes. 
It is suggested that this test provides data on one aspect 
of the phlogistic potential of skin immune deposits not 
detectable by direct immunofluorescence. 
Tissue deposits of immunoglobulins (lg) and complement are 
found in many autoimmune diseases. The presence of Ig may 
be due either to the local reaction between antigen and anti-
body, or to the deposition of circulating complexe.s. Whatever 
the mechanism by which immune complexes are formed, once 
they are present in tissue the ensuing phlogistic reaction is in 
part related to complement activation. 
The complement activating properties of immune deposits 
(ID) have until recently been inferred from the presence of 
complement proteins [1- 3]. Less attention has been given to 
detecting their biologic properties using functional assays. In 
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renal diseases, Uff, Evans, and Bartolotti [4) demonstrated 
ongoing complement activation by glomerular ID in many 
different types of nephritis. Interestingly, t he finding of differ-
ent complement proteins in deposits by direct immunofluores-
cence did not correlate with t he complement activating prop-
erties of these deposits; for instance in membranous glomeru-
lonephritis the heavy IgG and C3 deposits were inert. Little is 
known about complement activation by ID in the skin . The 
main reason for this is that normal skin cytoplasmic structures 
i.e., intermediate sized filaments, bind Cl and activate th~ 
classical pathway of complement (5-7]. Since linear structures 
are readily ident ified, Gammon and others could demonstrate 
complement activating deposits at the basal membrane zone 
(BMZ) in systemic lupus erythematosus, bullous pemphigoid, 
and pemphigus (eosinophilic spongiosis) [8-10) . However, com-
plement activation by perivascular deposits has not yet been 
investigated. We describe a simple method that, by avoiding 
complement activation by cutaneous structures, allowed us to 
study the capacity of skin ID- both perivascular and at the 
BMZ- to activate directly the alternative pathway of comple-
ment. 
MATERIALS AND METHODS 
Skin. biopsies 
Skin biopsies obtained under local anesthesia were taken from tissue 
samples submitted for routine direct immunofluorescence, freshly fro-
zen in liquid nitrogen and stored at - 70"C for less than 12 weeks. Ski n 
samples were grouped according to t he disease process as determined 
by clinical, histologic, and standard direct immunofluorescence (see 
Table If) . The biopsies were taken in lesiona l skin. 
Reagents 
The different reagents used as sources of comp lement were as 
follows. 
Normal complement: Normal human serum and normal gui nea pig 
(GP ) serum, both fresh or after storage at -70"C for less than 6 weeks. 
Reagents deficient in classical pathway fu.n.ction: Fresh human or GP 
serum treated with 10 mM ethylene glycol tetraacetate (EGTA) supple-
mented wit h 2 mM Mg++. C4.-deficient GP serum obtained fresh from 
C4-delicient guinea pigs (Porcellus, Heathlield, U.K.) . 
Reagents depleted of alternative pathway fu.n.ction: Fresh human and 
GP serum were heat inactivated at 50"C for 20 min before use so as to 
destroy factor B. Remaining alte rnative pathway function , tested by a 
solubilization assay [ 11], was less than 10% whereas t he CH50 was 80% 
of the untreated serum . 
Reagents withou.t complement fu.nction.: Sera were depleted of com-
plement by heat inactivation at 56"C for 1 h, or complement function 
was blocked by the addition of 10 mM EDTA. 
Fluorescein isothiocyanate-conjugated (FITC) ant ihuman lgG , lgA, 
lgM, and C3 sera were purchased from Behringwerke (Marburg, Ger-
many) . Molar fluorescein to protein ratio were: goat anti -IgG (-y chain), 
3.2; rabbit anti-IgM (!J. chain) , 1.5; rabbit anti-IgA (a chain), 3.4; and 
rabbit anti-C3, 2.6. All ant isera were used at a dilution of 1:10 in 
phosphate-buffered saline (PBS, Oxoid, Basinstoke, U.K.) so as to 
obtain between 50 and 100 11 g specific antibody/mi. FITC-conjugated 
lgG anti-GP C3 raised in goats was obtained from Nordic (Tillburg, 
The Netherlands); it conta ined 10 mg/ml of tota l labeled protein with 
a molar fluorescein to protein ratio of 2, and was used at a dilution of 
1:20 in PBS. 
408 SCHIFFERLl ET AL 
l mmunofluorescence Studies 
Standard direct immunofluorescence was performed on a ll skin 
biopsies. Briefly, 4 ,urn -thick cryostat sections of froze n unfixed skin 
biopsies were cut, a ir dried, and washed for 30 min in PBS. The ID 
were revealed by incubation with FlTC antihuman lg and C3 sera for 
30 min at room temperature. The sections were washed for 30 min in 
PBS, mounted in Fluoroprep (B iomerieux, Charbonnieres- les-Bains, 
France), and examined on a Zeiss microscope equipped with an epi-
scopic UV li ght syste m. Micrograp hs were taken with high-speed Ek-
tachrome ASA 400 film . 
Indirect immunoflu orescence studies for the detection of human and 
GP C3 were performed as follows. Cryostat sections were incubated 
with reagents diluted 1:10 in PBS for 15 min at 37' C to allow comple-
ment activation and C3 deposition. The sections were washed for 30 
min at room temperature and then processed with FITC anti -C3 
antisera as described above. In some experiments involving normal 
human skin sections, an additional incubation was first performed fo r 
5 min at 37' C with normal human serum diluted 1:10 in PBS. The 
appropriate GP reagents were added afte r wash ing with PBS for 15 
min at room temperature. When indicated, cryostat sections were 
incubated at 50' C for 20 min in a humid chamber so as to avoid 
desiccat ion. 
Cont rols: To see whether the goat anti -GP-C3 stained any human 
cutaneous structure, direct immunoi1uorescence was performed on 5 
normal and all pathologic skin biopsies. The cross- reactivity of anti-
human C3 and anti -GP C3 sera was assessed by indirect immunofluo-
. resce nce. Reagents used for indirect immunofluorescence studies of 
pathologic skin sections included: buffer only; normal human serum; 
normal, heat- inactivated, EDT A-treated, Mg EGTA-treated, C4-defi-
cient (in selected cases only) GP sera. 
Complement, Immune Complex, and Cryoglobulin Measurements 
C3 and C4 were measured by nephelometry usi ng specific goat 
antibodies (LAS-R, Hyland, Travenol, Belgium), and CH50 was deter-
mined acco rding to Mayer [12]. Hypocomplementemia was defined as 
1 of the 3 measurements being below the normal range; in fact all 
hypocomplementemic patients had a low CH00. Immune complexes 
were measured hy a [125l] Clq binding test [13]. Cryoglobulins were 
detected by the method of Brouet, Clauvel, Danon et al [14] and their 
content analyzed by standard immunoelectrophoresis. Results of these 
2 measurements ([125 l]Clq binding and cryoglobulins) were grouped 
together for statistical analys is; if 1 of the 2 measurements was positive, 
the serum was considered as conta ining immune complexes. 
RESULTS 
C3 Deposition. in. N ormal Human. Shin (Indirect 
Immunofluorescence) 
The co ndi t io ns which caused C3 deposition in human skin 
c ryostat section were identical for human serum + FITC anti-
human C3 and for GP serum + FITC anti -GP C3. There was 
no cross-reactivity between the two FITC anti-C3 antisera. 
R esults of GP C3 depos ition are shown in Table I. Using normal 
serum, GP C3 deposits were observed in dermal intracellular 
structures, particularly vascular endothelium and smooth mus-
cles . The C3 binding was very weak when a lternative pathway 
activity was destroyed (factor B-depleted reagent) and abol-
is hed when no complement activation could take place (heat-
inactivated or EDTA-chelated reagents ). In addition, no C3 
binding was seen when classical pat hway activation was blocked 
(Mg EGTA-trea ted GP or C4-deficient GP serum). However 
when a huma n C3 convertase was first a llowed to form on the 
cryostat section by preincubation with normal human serum 
(Table I , part B), the a lternative pathway of GP serum was 
capable of producing addit ional C3 binding. The presence of an 
a lternative pathway C3 convertase was further demonstrated 
by the presence of human C3 deposits and by exposing the 
cryostat section after the first incubation with human serum 
to a temperature of 50'C for 20 min so as to inactivate t he Bb 
fragment of the convertase (C3bBb) . After such inactivation 
further C3 deposition by the a lternative pathway of GP was 
abolished . 
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TABLE I. Guinea pig (G P) C3 deposition in normal human skin. 
Reagents used for incubations GP C3 deposits" 
A. 
B. 
One incubation with GP serum 
1. Normal serum 
2. Heat- inactivated serum (56'C) 
3. EDT A-treated serum 
4. C4 -deficient serum 
5. Mg-EGTA-treated serum 
6. Factor B-depleted serum (by 
heat: 50'C) 
Two incubation steps 
(first step 5 min at 37 ' C) 
1. No rmal human serum followed 
by: 
EDTA GP serum 
C4-de!icient GP serum 
Mg-EGTA-treated GP serum 
2. Normal human serum, t hen in-
cubation at 50'C for 20 min 
so as to destroy factor B, fol-
lowed by: 
C4-deficient GP serum 





"Detected by FITC anti-GP C3, fluorescence on normal cytoplasmic 
structures graded: - = negative, + = faint, ++ to ++++ = moderate 
to strong . 
TABLE II. Immunofluorescence results in pathologic skins 
Number of patients 
Direct 
Diagnosis in1munotluorescence 
GP C3 binding Total for human C3 
deposits (vessels/ test• 
BMZ) 
Discoid lupus erythem- 4 0/3 0 
atosus 






Cryoglobulinemia" 8 8/0 7 
Skin vasculitish 8 8/0 4 
Skin lesions with pre- 8 4/1 1" 
dominant IgA depos-
its' 
Cold agglutinin disease 1/0 0 
Bullous pemphigoid 5 0/5 0 
P ityriasis lichenoides 4 0/01 0 Psoriasis 7 0/ 01 0 Others" 15 12/ 0 0 
"Four type II mixed essential cryoglobulinemia (3 with monoclonal 
lgMk + polyclonal lgG, 1 with monoclonal IgAk + polylconal IgG); 4 
type Ill (1 associated with rheumatoid arthritis, 1 associated with 
lymphoma, 2 essential). 
b Vasculitis involving the skin only; 3 presented typical leukocyto-
clastic lesions by histologic examination. 
' Three with dermatitis herpetiformis, 3 linear lgA dermatosis, 1 
Henoch-Schiinlein purpura, 1 alcoholic cirrhosis wi th skin vasculitis. 
"Various inflammatory skin lesions without evidence for vasculitis 
by histologic examination; most were selected because vascular C3 
deposits were observed by direct immunofluorescence. 
' Positive in 2 for both locations. 
1 Very faint granular C3 deposition at the BMZ was considered as 
negative. 
" Reagent used for the first incubation: Mg-EGTA-treated GP serum. 
"Positive on ly for vascu lar deposits. 
GP C3 Deposition in Shin S ections of Patients with Various 
Diseases 
The results obtained with normal skin biopsies led to the use 
of Mg EGTA-treated serum to study the alternative pathway 
activation (APA) capacity of pathologic skin cryostat section 
(= GP C3 binding test, Table II). In selected cases the mecha-
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F IG 1. Immunofluorescence of a patient with skin vasculitis . a, 
Direct fluorescence with antihuman C3 showing vascular deposits. b, 
GP C3 binding test. The cryostat section was first overlaid with GP 
serum in the presence of 2 mM Mg a nd 10 mM EGTA for 15 min at 
37"C. GP C3 was revealed with specific a ntiserum. Note GP C3 depo-
sition in a similar vascular site. X 250. 
nism of this binding was confirmed by C4-deficient serum. Of 
66 biopsies studied, significant human C3 deposits were ob-
served by direct immunofluorescence in 46 (34 in vessels only, 
10 at the BMZ, 2 in both locations) . The GP C3 binding test 
to evaluate activation of the alternative pathway was positive 
in 15. The GP C3 was localized only in and around vessels. 
Only specimens positive for C3 by direct immunoflu~rescence 
at similar vascular sites showed evidence for alternative path-
way activation (APA) (Fig 1). By seria l sectioning APA corre-
sponded exactly to human C3 deposits. However, the presence 
of human C3 in vessels did not always indicate AP A, since 21 
biopsies with such deposits were negative in the GP C3 binding 
test. Furthermore, even strong human C3 deposits were not 
indicative of APA. No GP C3 binding occurred in the control 
experiments of the 15 specimens showing APA (EDTA GP 
serum, heat-inactivated GP serum, human serum, buffer only). 
Occasionally G P C3 antibody was found in cells of heavy 
cellular infiltrates, but this was observed even when no GP 
serum was used. This nonspecific binding of GP C3 antibody 
could, however, be easily differentiated from vascular deposits. 
APA was shown only in skin specimens with histologic evidence 
of vasculitis; the 2 posit ive biopsies of patients with systemic 
lupus erythematosus also showed vasculitis with C3 deposits. 
Fifty percent of the patients presenting skin vasculitis were 
positive; it is interesting to note that human C3 deposits were 
found in t he 3 patients with typica l histologic lesions of leu-
kocytoclastic skin vascul itis, but in none did these deposits 
produce loca l APA. No linear GP C3 deposition at the BMZ 
FIG 2. Patient with rheumatoid arthriti s and generalized vasculitis 
(presence of a cryoglobulin type III , polyclonal IgM and IgG). a, The 
GP C3 binding test showed deposits in and around vessels. This 
evidence for APA corresponded to C3, IgG, and IgM deposits by direct 
immunofluorescence. b, After preincubation of the cryostat section at 
5o·c for 20 min, the G P C3 deposits remained present, suggesting that 
immunoglobulin deposits were able to activate directly the alternative 
pathway of complement. x 160. 
was observed in any of the patients with linear lg and/or C3 
deposits. There was no GP C3 deposition in 5 normal skin 
specimens and in 14 inflammatory skin lesions in which neither 
immunoglobulin nor C3 was observed by direct immunofluo-
rescence (psoriasis, pityriasis lichenoides, others). 
Direct classical pathway activation by deposits at the BMZ 
could be evaluated since all cryostat sections were also exposed 
to normal GP serum. Positive linear staining was detected in 2 
patients with bullous pemphigoid and in 3 with systemic lupus 
erythematosus. 
Cryostat sections of biopsies showing APA were preincubated 
at 50"C for 20 min so as to inactivate the alternative pathway 
C3 convertase before repeating the assay. Due to the lack of 
sufficient material, only 10 of the 15 biopsies could be evaluated. 
APA was abolished by this treatment in 6, whereas in the 4 
remaining, GP C3 binding remained detectable in many vessels 
(Figs 2, 3) . 
The evidence for APA in specimens correlated significantly 
with the presence of C3 and lgM deposits by direct immunoflu-
orescence (Table III) . The presence of immunoglobulins in 
addition to C3 increased the likelihood of AP A but not to a 
significant level. 
In those patients where cryoglobulins and/or immune com-
plexes, and complement were measured, APA was found to be 
significantly associated with the presence of circulating com-
plexes and with hypocomplementemia (Table IV). All speci-
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F IG 3. Pa t.ienL with mixed essential cryoglobulinemia type II (lgMk-
lgG) . a, Positive GP C3 binding Lest showing vascular deposits. b, After 
exposure to 50 ' C for 20 min a similar sectwn showed no more GP C3 
deposits. This suggests that APA was due to the presence of a heat-
labile C3 co nvertase (C3bBb). X 160. 
TABLE III. Relationship between the type of immune deposit by direct 
immunofluorescence and a positive guinea pig C3 binding test 
Number of patients 
Type of Positi ve 
immune GP C:l deposit T otal Bindinr: 
test 
None 14 0 
lg only 6 0 
C3 only 22 4 
C3 and lg (l) " 14 6 
C3 and lg (2)" 8 3 
C3 and lg (3)" 2 2 
Total with C3 46 15 
lgA present'' 16 5 
lgG present" 13 4 
lgM present'' 15 9 
Total number 
of patients 66 15 
} 
p Value (corrected 
chi square) 
together 
p = 0.09< 
p < 0.01 
p = nsd 
p = nsd 
p < 0.0005 
" Number of lg classes present. 
"Presence of Ig class either alone or with other lg and C3. 
,. Compared to number of patients with C3 deposits on ly. 
d ns = Not significant. 
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TABLE IV. Serologic comparisons of patients with (+) and without (- ) 
guinea pig C3 binding 
Hypocomplementemic" 
(1 2/26) 
Presence of circulating 
immune complexes 
and/or cryoglobulins" 










p < 0.0005 
p < 0.03 
• As defined in MateriaL~ and Methods/total of patients in whom 
measurements were done. 
DISCUSSION 
The GP C3 binding test described here allowed the evaluation 
of the capacity of skin immune deposits to activate the a lter-
native pathway of complement ; thus it provided a simple tool 
to study one of the biologic properties of immune reactants 
detected in t he skin by standard direct immunofluorescence. 
The main findings were that (1) APA could be demonstrated 
when human C3 deposits were seen by direct immunofluores-
cence but not all C3 deposits were found to activate the alter-
native pathway; (2) such activation was restricted to vascu lar 
deposits; (3) the phlogistic potential of t he ID correlated with 
serologic evidence of ongoing immune reactions, i.e., hypocom -
plementemia and circulating immune complexes. 
Deposition of GP C3 in our assay was related to APA since 
Mg EGTA-chelated GP serum was used. In some cases th is was 
confirmed by the use of C4-deficient GP serum. Treatment of 
serum with EDTA or heat inactivation abolished GP C3 dep-
osition in all cases so t hat direct enzymatic cleavage and 
binding of C3 fragments was unlikely. Furthermore, t he speci-
ficity of the reaction was demonstrated by the absence of 
evidence for AP A in many inflammatory skin lesions not 
thought to be mediated by immune complexes, and by the 
localization of GP C3 in no structure other than vascular walls 
known to contain ID by direct t1uorescence. A heterogeneous 
group of patients was investigated in t his study so that firm 
conclusions cannot be drawn in any specific disease. However 
a general observation can be made: some ID containing C3 
provided the substrate necessary to produce amplification of 
complement activation by the alternative pathway. The period 
of time for which such deposits were a lternative pathway acti-
vators was not determined by serial biopsies; it could well be 
t hat many of t he ID incapable of AP A had previously been 
activators as well. Since APA was demonstrated only for some 
vascular ID it is possible that such activation was restricted to 
freshly deposited complexes. 
No APA could be detected in most specimens with predom-
inant lgA deposits. This finding contrasts with good evidence 
for APA by IgA complexes or aggregates [15]. However not all 
IgA-containing complexes activate the alternative pathway 
[16- 18]. Furthermore, it could well be t hat once deposited, IgA 
had been modified by local enzymatic reactions so as to lose 
some biologic properties. 
The absence of APA in t he 3 patients with leukocytoclastic 
skin vasculitis was not surprising. It is likely that in this type 
of disease, the pathologic process is similar to the experimental 
Arthus reaction, i.e., immune complex deposition, complement 
activation, and polymorphonuclear leukocyte attraction leading 
to rapid elimination of the offending complexes [18]. By the 
time polymorphonuclear infiltration is evident on biopsies, the 
initial reaction is probably over. 
Some specimens with linear deposits at the BMZ were able 
mens from patients with cryoglobulinemia were positive for 
APA except one; in that patient the cryoglobulin contained a 
monoclonal IgAk + polyclonal lgG and the serum complement 
was normal. 
to activate the classical pathway of complement as reported by 
others [8- 10] but none produced direct APA. This suggests 
that despite possible ongoing complement activation, the in-
activation of t he alternative pathway C3 convertase is rapid in 
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such deposits in vivo, thus precluding amplification of the 
complement cascade. 
By heating the cryostat sections first so as to destroy Factor 
B (50oC for 20 min), it was possible to iden t ify two different 
mechanis ms responsible for APA: heat stable activation-pre-
sumably by immune aggregates-and heat labile activation-
presumably by the alternative pathway C3 convertase, C3bBb. 
Not enough biopsies have been studied to a llow correlations 
with histo logic or immunologic findings. 
Histamine injection induces immune deposition followed by 
local vasculitis in many patients with immune complex-me-
diated diseases . The reactants deposited most often at the time 
of this test are IgM and C3 (19-22]; it is interesting to note 
that in our assay ongoing APA was significantly associated 
with IgM and C3 deposits suggesting that such deposits might 
be of pathophysiologic significance. 
Large amounts of circulating immune complexes and hypo-
complementemia were demonstrated in most patients with 
evidence of APA. It is probable that these circu lating complexes 
were not on ly directly responsible for complement depletion in 
the blood, but also produced complement activation at the site 
of their tissue deposition. In addition, since immune aggrega-
tion is blocked by complement it is possible that the hypocom-
plementemic state of t hese patients enhanced the formation of 
large insoluble complexes more likely to deposit in vascu lar 
walls (23]. Such freshly deposited immune aggregates would be 
responsible for the ensuing alternative pathway activation and 
t hus for the phlogistic reaction, since chemotactic (C3a) and 
anaphy latoxic (C3a, C5a) complement fragments are released 
(24]. 
In conclusion, the simple GP C3 binding test described in 
this paper provided data on one aspect of the phlogistic poten-
tial of skin immune deposits not detectable by direct immuno-
fluorescence. Further studies are required to better define the 
role of the alternative pathway in the modulation of the inflam-
matory react ion in the skin. In addition, other assays should 
be devised to test the capac ity of vascular immune reactants to 
activate the classical pathway of complement. 
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REFERENCES 
1. Sams WM C la~an HN Kohler PF, Mcintosh RM, Small P, Mass 
MF: Hu~1an necrotizing vasculitis: immunoglobulins and com-
plement in vessel walls of cutaneous les ions and normal skin. J 
Invest Dermatol 64:441- 445, 1975 
2. Provost TT T omasi TB: Evidence for complement activation via 
the a lten{ative pathway in skin diseases. L Herpes gestationis, 
system ic lupus erythematosus, and bu llous pemph1go1d. J Chn 
Invest 52:1779- 1787, 197 
3. Cream J ,J: Immunofluorescence studies of the skin in cryoglobu li -
neamic vascu li t is. Br J Dermato l 84:48-53, 1971 
4. Uff JS, Evans DJ, Bartolotti SR: In vitro fixation of guinea pig 
complement by renal biopsies. J Clm Lab lmmunol 1:299- 304, 
1979 
5. Schuler G, Hintner H, Wolff K, Fritsch P, Sting! G: In vitro 
complement binding on cytop lasmic structures in normal human 
skin: immunoelectronmicroscopic studies. J Cell Bioi 95:543-
551, 1982 
6. Linder E: Antibody independent binding of Clq and activation of 
serum complement by human skin in vitro. J Invest Dermatol 
78:116- 120, 1982 
7. Hintner H, Sting! G, Schuler G, Wolff K: ln vitro complement 
binding on cytoplasmic structures in normal human sk in: I. 
Immunofluorescence studies. J Invest Dermatol 79:119- 124 
1982 , 
8. Gammon WR, Merritt CC, Henke DC, Robinson T , Henley N, De 
Angelo L: Complement activating immune deposits in systemic 
lupus erythematosus sk in. J Invest. Dermatol 81 :1 4-20, 1983 
9. Gammon WR, Merritt CC, Lewis DM, Sams WM, Wheeler CE, 
Carlo JR: Functional evidence for complement activating im-
mune complexes in the skin of patients with bullous pemphigoid. 
J Invest Dermatol 78:52-57, 1982 
10. Iwatsuki K, Tagami H, Yamada M: Pemphigus antibodies mediate 
the development of an inflammatory change in the epidermis. 
Acta Derm Venereol (Stockh) 63:495-500, 1983 
11. Schifferl i JA, Morris SM, Dash A, Peters DK: Complement-me-
dia ted solubilization in patients with systemic lupus erythema-
tosus, nephritis or vasculitis. Clin Exp Immun ol 46:557- 564 
1981 , 
12. Mayer MM: Complement and complement fixation , Experimental 
Immunochemist ry, 2d ed. Edi ted by EA Kabat, MM Mayer. 
Springfield, IL. Charles C Thomas, 1961, p 133 
13. Zubler RH, Longe G, Lambert PH, Miescher PA: Detection of 
immune complexes in unheated sera by a modified 125Ciq binding 
test. J lmmunol 116:232-235, 1976 
14 . BrouetJC, Clauvel JP, Danon F, Klein M, Seligmann M: Biological 
and clinical significance of cryoglobulins: a report of 86 cases. 
Am J Med 57:775- 788, 1974 
15. Pfaffenbach G, Lamm ME, Gigli I: Activation of the guinea pig 
alternative complement pathway by mouse lgA immune com-
plexes. J Exp Med 155:231- 247, 1982 
16. Garcia-Fuentes M, Chatler C, Williams DG: Cryoglobulinemia in 
Henoch -Schonlein purpura. Br Med J 2:163- 165, 1977 
17. Adu 0 , Williams DG: Complement activating cryoglobulins in the 
nephritis of systemic lupus erythematosus. Clin Exp Jmmunol 
55:495-501, 1984 
18. Cream JJ, Bryceson ADM , Ryder G: Disappearance of immuno-
globu lin and complement from the Arthus reaction and its rele-
vance to studies of vasculitis in man. Br J Derma to! 84:106- 109 
1971 , 
19. Jorizzo JL, Daniels JC, Apisarnthanarax P , Gonzalez EB, Cavallo 
T: Histamine-triggered localized vascu li tis in patients with ser-
opositive rheumatoid arthritis. J Am Acad Dermatol 9:845- 851 
1983 , 
20. Gower RG, Sams WM, Thorne EG, Kohler PF, Claman HN: 
Leucocytoclastic vasculi tis: sequentia l appearance of immuno-
reacta nts and cellular cha nges in serial biopsies. J Invest Der-
matol 69:477-484, 1976 
21. Braverman IM, Yen A: Demonstration of immune comp lexes in 
spontaneous and histamine- induced lesions and in normal skin 
of pat ients with leucocytoclastic angiitis. ,J Invest Dermatol 
64:105- 112, 1975 
22. Wolff HH, Maciejewski W, Scherer R, Braun-Falco 0: lmmunoe-
lectronrnicroscopic examination of early lesions in histamine 
induced immune complex vasculitis in man. Br J Dermatol 
99:13- 24, 1978 
23. Schifferli JA, Peters DK: Complement, the immune complex lat-
tice, a nd the pathophysiology of complement deficiency syn-
drome. Lancet 2:957-959, 1983 
24. Hugli TE: Structure and function of the anaphylatoxins. Springer 
Semin Immunopathol 7:193-219, 1984 
